KUALA LUMPUR: Apex Healthcare Bhd recorded a web revenue of RM14.01mil within the third quarter ended Sept 30, 2021, which was virtually on par with the online earnings of RM14.22mil posted within the earlier corresponding quarter.
Income for the quarter beneath evaluate was RM211.06mil, a 24.8% enchancment over the comparative quarter as a result of considerably increased market demand for prescribed drugs, diagnostics and shopper healthcare.
It mentioned in a bourse submitting that income development was additionally helped by sturdy market demand for pulse oximeters, surgical masks, Covid-19 self-test kits in Malaysia and SinoPharm and SinoVac Covid-19 vaccines in Singapore.
Over the 9 months to Sept 30, Apex posted a web revenue of RM38.71mil, 7% decrease than in the identical interval final yr.
Income was increased at RM573.1mil, 6.69% improved from RM537.15mil within the comparative interval.
On prospects, the group mentioned it maintains its cautious stance and expects the enterprise atmosphere to remain difficult for the remainder of the present monetary yr and into 2022.
“Additional unexpected market modifications and developments apart, the Group expects to ship a passable efficiency for the present monetary yr,” it added.